Affiliation:
1. Durata Therapeutics, Branford, Connecticut, USA
2. JMI Laboratories, North Liberty, Iowa, USA
Abstract
ABSTRACT
In over a decade (2002 to 2012) of
Staphylococcus aureus
surveillance testing on 62,195 isolates, dalbavancin was demonstrated to be active against isolates that were either susceptible or nonsusceptible to daptomycin, linezolid, or tigecycline. Nearly all (99.8%) multidrug-resistant methicillin-resistant
S. aureus
isolates were inhibited by dalbavancin at ≤0.12 μg/ml (MIC
50/90
, 0.06/0.06 μg/ml), the current U.S. Food and Drug Administration (U.S. FDA) breakpoint. Overall, only 0.35% of the monitored
S. aureus
isolates had a dalbavancin MIC of either 0.25 or 0.5 μg/ml (i.e., were nonsusceptible).
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference10 articles.
1. Serious Infections Caused by Methicillin‐ResistantStaphylococcus aureus
2. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
3. MRSA: the first half century
4. Dalvance. 2014. Dalvance (dalbavancin) for injection, for intravenous use. Durata Therapeutics U.S. Limited, Chicago, IL. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021883s000lbl.pdf.
5. Semisynthetic glycopeptides: chemistry, structure-activity relationships and prospects;Ciabatti R;Farmaco,1997
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献